444 related articles for article (PubMed ID: 23557632)
1. Prion protein oligomer and its neurotoxicity.
Huang P; Lian F; Wen Y; Guo C; Lin D
Acta Biochim Biophys Sin (Shanghai); 2013 Jun; 45(6):442-51. PubMed ID: 23557632
[TBL] [Abstract][Full Text] [Related]
2. Prion protein: structural features and related toxicity.
Hu PP; Huang CZ
Acta Biochim Biophys Sin (Shanghai); 2013 Jun; 45(6):435-41. PubMed ID: 23615535
[TBL] [Abstract][Full Text] [Related]
3. The Unexposed Secrets of Prion Protein Oligomers.
Wang G; Wang M; Li C
J Mol Neurosci; 2015 Aug; 56(4):932-937. PubMed ID: 25823438
[TBL] [Abstract][Full Text] [Related]
4. The emerging principles of mammalian prion propagation and transmissibility barriers: Insight from studies in vitro.
Surewicz WK; Jones EM; Apetri AC
Acc Chem Res; 2006 Sep; 39(9):654-62. PubMed ID: 16981682
[TBL] [Abstract][Full Text] [Related]
5. Experimental approaches to the interaction of the prion protein with nucleic acids and glycosaminoglycans: Modulators of the pathogenic conversion.
Silva JL; Vieira TC; Gomes MP; Rangel LP; Scapin SM; Cordeiro Y
Methods; 2011 Mar; 53(3):306-17. PubMed ID: 21145399
[TBL] [Abstract][Full Text] [Related]
6. Molecular Mechanism of the Misfolding and Oligomerization of the Prion Protein: Current Understanding and Its Implications.
Singh J; Udgaonkar JB
Biochemistry; 2015 Jul; 54(29):4431-42. PubMed ID: 26171558
[TBL] [Abstract][Full Text] [Related]
7. Molecular dynamics studies on the NMR and X-ray structures of rabbit prion proteins.
Zhang J; Zhang Y
J Theor Biol; 2014 Feb; 342():70-82. PubMed ID: 24184221
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human prion protein fragment 90-231, a useful model to study prion neurotoxicity.
Corsaro A; Thellung S; Villa V; Nizzari M; Aceto A; Florio T
OMICS; 2012; 16(1-2):50-9. PubMed ID: 22321015
[TBL] [Abstract][Full Text] [Related]
9. Generation of genuine prion infectivity by serial PMCA.
Weber P; Giese A; Piening N; Mitteregger G; Thomzig A; Beekes M; Kretzschmar HA
Vet Microbiol; 2007 Aug; 123(4):346-57. PubMed ID: 17493773
[TBL] [Abstract][Full Text] [Related]
10. Residue-specific mobility changes in soluble oligomers of the prion protein define regions involved in aggregation.
Glaves JP; Ladner-Keay CL; Bjorndahl TC; Wishart DS; Sykes BD
Biochim Biophys Acta Proteins Proteom; 2018 Sep; 1866(9):982-988. PubMed ID: 29935976
[TBL] [Abstract][Full Text] [Related]
11. PrP N-terminal domain triggers PrP(Sc)-like aggregation of Dpl.
Erlich P; Cesbron JY; Lemaire-Vieille C; Curt A; Andrieu JP; Schoehn G; Jamin M; Gagnon J
Biochem Biophys Res Commun; 2008 Jan; 365(3):478-83. PubMed ID: 17997980
[TBL] [Abstract][Full Text] [Related]
12. Preventing misfolding of the prion protein by trimethylamine N-oxide.
Bennion BJ; DeMarco ML; Daggett V
Biochemistry; 2004 Oct; 43(41):12955-63. PubMed ID: 15476389
[TBL] [Abstract][Full Text] [Related]
13. PrP(Sc) of scrapie 263K propagates efficiently in spleen and muscle tissues with protein misfolding cyclic amplification.
Shi S; Dong CF; Wang GR; Wang X; An R; Chen JM; Shan B; Zhang BY; Xu K; Shi Q; Tian C; Gao C; Han J; Dong XP
Virus Res; 2009 Apr; 141(1):26-33. PubMed ID: 19162101
[TBL] [Abstract][Full Text] [Related]
14. Disease-associated F198S mutation increases the propensity of the recombinant prion protein for conformational conversion to scrapie-like form.
Vanik DL; Surewicz WK
J Biol Chem; 2002 Dec; 277(50):49065-70. PubMed ID: 12372829
[TBL] [Abstract][Full Text] [Related]
15. Molecular dynamics studies on 3D structures of the hydrophobic region PrP(109-136).
Zhang J; Zhang Y
Acta Biochim Biophys Sin (Shanghai); 2013 Jun; 45(6):509-19. PubMed ID: 23563221
[TBL] [Abstract][Full Text] [Related]
16. Conformational conversion of prion protein in prion diseases.
Zhou Z; Xiao G
Acta Biochim Biophys Sin (Shanghai); 2013 Jun; 45(6):465-76. PubMed ID: 23580591
[TBL] [Abstract][Full Text] [Related]
17. In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrP(Sc).
Bocharova OV; Breydo L; Parfenov AS; Salnikov VV; Baskakov IV
J Mol Biol; 2005 Feb; 346(2):645-59. PubMed ID: 15670611
[TBL] [Abstract][Full Text] [Related]
18. Monitoring prion protein stability by NMR.
Julien O; Graether SP; Sykes BD
J Toxicol Environ Health A; 2009; 72(17-18):1069-74. PubMed ID: 19697241
[TBL] [Abstract][Full Text] [Related]
19. The structure of prion: is it enough for interpreting the diverse phenotypes of prion diseases?
Tian C; Dong X
Acta Biochim Biophys Sin (Shanghai); 2013 Jun; 45(6):429-34. PubMed ID: 23459557
[TBL] [Abstract][Full Text] [Related]
20. Strain-specific effects of reducing agents on the cell-free conversion of recombinant prion protein into a protease-resistant form.
Imamura M; Kato N; Okada H; Iwamaru Y; Shimizu Y; Mohri S; Yokoyama T
Microbiol Immunol; 2011 Sep; 55(9):633-40. PubMed ID: 21645053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
